Welcome to Jianke online pharmacy! Sign in Free registration
reminder:The pictures are the real photos of the original products taken by Jianke for reference only; In case of new packaging listing, there may be update lag, please take the physical object as the standard!
Baidu certification

Duloxetine hydrochloride enteric coated capsule (xinbaida)

It is used to treat depression and generalized anxiety disorder. More role
App download minus 10 yuan
Common name:
Duloxetine hydrochloride enteric coated capsule
Product No.:
B14201011861
Approval No.:
H20150287 (original h20110320) (inquired by the State Drug Administration)
Jianke price:
¥293.48
Product specification:
60mg*14s 30mg*7s
Manufacturer:
Lilly del Caribe,Inc.
number        Quantity:
Add to list
Tips:
This product is a prescription drug. Please buy it with the prescription paper; Delivered by Jianke offline drugstore
 
(for assistance, please call400-086-5111
Jianke promises:
Genuine guarantee
Bank remittance / transfer online payment
  • Product introduction
  • instructions
  • Qualification certificate
  • Relevant information
Product name Duloxetine hydrochloride enteric coated capsule (xinbaida)
Main raw materials Duloxetine hydrochloride.
Main role It is used to treat depression and generalized anxiety disorder.
Product specification 60mg*14s
Usage and dosage Initial treatment: the initial dose of xinbaida duloxetine hydrochloride enteric coated capsule is recommended to be 40mg / day (20mg twice a day) to 60mg / day (once a day or 30mg twice a day), regardless of food consumption. The existing clinical research data do not confirm that the dose of more than 60mg / day will increase the curative effect. Maintenance / continuous / long-term treatment: it is generally believed that the acute attack of depression needs several months or more of drug treatment, but there is not enough experimental data to determine how long patients should take duloxetine continuously. For such patients, the necessity of maintenance treatment and the corresponding required dose should be regularly evaluated. Special population: dosage for patients with impaired renal function 1 for patients with advanced renal disease (requiring dialysis) or patients with severe renal function impairment (estimated creatinine clearance rate < 30 ml / min), it is recommended not to use this product (see pharmacology and Toxicology). Dosage for patients with liver insufficiency 1. It is recommended that patients with any liver insufficiency avoid taking this product (see pharmacology, toxicology and precautions) dosage for elderly patients 1. For elderly patients, it is not recommended to adjust the dose according to age. As with any drug, care should be taken in the treatment of elderly patients. When adjusting the dose individually in elderly patients, additional care should be taken when increasing the dose. Treatment of female patients in the third month of pregnancy - newborns exposed to SSRIs or snrls (serotonin and norepinephrine reuptake inhibitors) within the third month of pregnancy will have complications that will lead to prolonged hospital stay, respiratory support and tube feeding (see Notes). See the inner packaging instructions for details.
manufacturing enterprise Lilly del Caribe,Inc.
Jianke commitment
  • Genuine guarantee, formal invoice

    Jianke.com is an approved (B2C) Internet drug legitimate business enterprise in Guangdong Province. It signs a direct supply agreement with the manufacturer and can issue formal invoices for the purchased goods.

  • Private packaging, privacy protection

    When jianke.com packages and delivers goods, the appearance of the packing box only displays the necessary information for delivery, and the name of the purchased goods will not appear. The specific shopping list is in the package to protect the privacy of customers.

  • Efficient logistics and safe arrival

    All products of jianke.com adopt the door-to-door distribution mode of third-party logistics. They are delivered to the nearest warehouse according to your distribution address, so as to deliver them to you on time.

  • Three warehouses to ensure inventory

    Jianke.com has three warehouses in Guangzhou, Dongguan and Wuhan, equipped with first-class equipment, constant temperature and humidity to ensure drug quality. Specially assigned person to manage and ensure product inventory.

[drug name] Duloxetine hydrochloride enteric coated capsule (xinbaida)

[common name] Duloxetine hydrochloride enteric coated capsule

[specification and model] 60mg*14s

[manufacturer] Lilly del Caribe,Inc.

[drug type] Western medicine

[approval No.] H20150287 (original h20110320)

[validity period] 36 months

[functional indications] It is used to treat depression and generalized anxiety disorder.

[usage and dosage] Initial treatment: the initial dose of xinbaida duloxetine hydrochloride enteric coated capsule is recommended to be 40mg / day (20mg twice a day) to 60mg / day (once a day or 30mg twice a day), regardless of food consumption. The existing clinical research data do not confirm that the dose of more than 60mg / day will increase the curative effect. Maintenance / continuous / long-term treatment: it is generally believed that the acute attack of depression needs several months or more of drug treatment, but there is not enough experimental data to determine how long patients should take duloxetine continuously. For such patients, the necessity of maintenance treatment and the corresponding required dose should be regularly evaluated. Special population: dosage for patients with impaired renal function 1 for patients with advanced renal disease (requiring dialysis) or patients with severe renal function impairment (estimated creatinine clearance rate < 30 ml / min), it is recommended not to use this product (see pharmacology and Toxicology). Dosage for patients with liver insufficiency 1. It is recommended that patients with any liver insufficiency avoid taking this product (see pharmacology, toxicology and precautions) dosage for elderly patients 1. For elderly patients, it is not recommended to adjust the dose according to age. As with any drug, care should be taken in the treatment of elderly patients. When adjusting the dose individually in elderly patients, additional care should be taken when increasing the dose. Treatment of female patients in the third month of pregnancy - newborns exposed to SSRIs or snrls (serotonin and norepinephrine reuptake inhibitors) within the third month of pregnancy will have complications that will lead to prolonged hospital stay, respiratory support and tube feeding (see Notes). See the inner packaging instructions for details.

[adverse reactions] In the placebo-controlled study of MDD in the acute phase, the incidence of ≥ 2% and adverse reactions in the duloxetine group were higher than those in the placebo group. The most common adverse reactions (incidence ≥ 5%, and at least twice that of placebo group) include nausea, dry mouth, constipation, loss of appetite, fatigue, sleepiness and increased sweating (please consult a specialist for details). Urgent urination duloxetine is a known drug affecting urethral resistance. If urgent urination occurs during duloxetine treatment, the possibility of drug-induced urination should be considered. Laboratory changes - in the 9-week MDD or 13 week DPNP placebo-controlled study, the mean values of alt, AST, Cpk and alkaline phosphatase (vinegar) increased slightly after duloxetine treatment compared with baseline. Compared with the placebo group, these abnormal values occurred in duloxetine treated patients, which showed occasional, moderate and transient abnormalities (see Precautions). Changes in vital signs - in a 9-week MDD placebo-controlled study, duloxetine at a dose of 40-120 mg / day resulted in an increase in blood pressure. Compared with placebo, systolic blood pressure increased by an average of 2 mmHg, diastolic blood pressure increased by an average of 0.5 mmHg, and the incidence of systolic blood pressure exceeding 140 mmHg increased. In the 9-week MDD and 13 week DPN cadaveric placebo-controlled study, duloxetine treatment resulted in a slight increase in heart rate, about 2 times / min compared with placebo. (see the inner packaging manual for details).

[precautions] General precautions Hepatotoxicity - duloxetine is at risk of increasing serum aminotransferase levels. Elevated liver transaminase resulted in discontinuation of treatment in patients treated with 0.4% (31 / 8454) duloxetine. The median time of transaminase elevation in these patients was 2 months. In the controlled trial in patients with depression, 09% (8 / 930) of patients treated with duloxetine increased ALT more than three times the upper limit of normal, compared with 0.3% (2 / 652) in the placebo group. In all placebo-controlled studies, 1% (39 / 3732) of patients in duloxetine group had more than three times higher ALT than the upper limit of normal, compared with 0.2% (6 / 2568) in placebo group. In the fixed dose placebo-controlled study, there is evidence that the increase of ALT exceeds the upper limit of normal by 3 times and the increase of AST exceeds the upper limit of normal by 5 times, which has a dose-response relationship with the drug dose. Duloxetine is not usually used in patients with habitual drinking and chronic liver disease. Blood pressure should be measured before treatment and regularly after treatment. Duloxetine should be used with caution in patients with alcohol use or previous history of liver disease. Duloxetine should be used with caution in patients with a history of seizures. Duloxetine should be used with caution in patients with a previous history of mania Withdrawal - withdrawal symptoms of duloxetine have been systematically studied. In a 9-week placebo-controlled trial in patients with depression, the occurrence rate of patients treated with duloxetine was 2% or significantly higher than that of placebo. The symptoms included dizziness, nausea and headache.? (see the inner packaging manual for details). Please read the instructions carefully and follow the doctor's advice.

[taboo] ◇ ► ◄ duloxetine enteric coated capsules should not be used in patients who are known to be allergic to duloxetine enteric coated capsules or any inactive ingredients in products. ◇ do not use in combination with monoamine oxidase inhibitors (MAOIs). (see warning) ◇ untreated narrow angle glaucoma ◇ clinical trials show that duloxetine increases the risk of mydriasis. Untreated patients with narrow angle glaucoma should avoid duloxetine

[listing Permit Holder] Eli lillyand company (USA)

[packaging unit] box

[main ingredients] Duloxetine hydrochloride.

[character] Opaque green capsule and blue capsule cap, with 60mg printed on the capsule.

[applicable population] adult

[medication for pregnant and lactating women] Pregnancy: Pregnancy classification C - in animal reproductive studies, duloxetine was found to have adverse effects on embryo / fetus and postnatal development. Duloxetine was orally administered to rats and rabbits during organogenesis of embryos at a dose of 45mg / kg / day (the dose of rats was 7 times [mrhd, 60mg / kg / day], 4 times the human dose calculated according to body weight / body surface area index 120mg / day; the dose of rabbits was 15 times [mrhd], 7 times the human dose calculated according to body weight / body surface area index 120mg / day), and no teratogenic effect was found. At this dose, fetal weight decreases. The non effective dose is 10mg / kg / day (twice as much as [mrhd] in rats, about 1 times as much as the human dose calculated according to body weight / body surface area index 120mg / day; the rabbit dose is 3 times as much as [mrhd], about 2 times as much as the human dose calculated according to body weight / body surface area index 120mg / day). Duloxetine was used during pregnancy. Non teratogenic effects - complications in newborns exposed to SSRIs or SNRIs (serotonin and norepinephrine reuptake inhibitors) during the third trimester of pregnancy can lead to prolonged hospitalization, respiratory support and tube feeding. These complications occur immediately after birth. The existing clinical findings include respiratory distress, cyanosis, apnea, seizures and temperature instability, feeding difficulties, vomiting, hypoglycemia, dystonia, increased muscle tone, hyperreflexia, tremor, overreaction, irritability and crying. These feelings

[medication for children] The efficacy and safety of duloxetine in children are unclear (see warning). If duloxetine is considered for use in children and adolescents, the potential risks and clinical needs must be weighed.

[medication for elderly patients] Of the 2418 patients in the clinical study of duloxetine in the treatment of depression (MDD), 5.9% (143) were patients over 65 years old. No significant differences in safety and efficacy were observed between these patients and young patients, and no significant differences between the elderly and young people were found in other clinical reports, but the increased sensitivity of some elderly patients cannot be ruled out.

[storage] Store at room temperature of 15 ~ 30 ℃

Praise degree

zero%

    reminder

    Dear customer:

    In case of emergency, please call the ordering hotline400-086-5111Consult a health care professional pharmacist.

    Duloxetine hydrochloride enteric coated capsule (xinbaida)

    ¥293.48

    reminder

    To ensure your privacy, please enter the verification code and click "confirm callback". Our customer service staff will call back the phone number you entered later!

    Please enter the correct verification code!
    Loding...
    Can't see clearly. Change one

    Dear customer:

    Your callback failed this time. Please re-enter the verification code to try. Thank you!